Literature DB >> 24799542

Delayed diagnosis and false relapse due to paternal testosterone use in adrenocortical carcinoma.

Adam L Green1, Abhinash Srivatsa2, Carlos Rodriguez-Galindo3.   

Abstract

The prognosis of pediatric adrenocortical carcinoma often depends on prompt diagnosis to begin treatment before metastatic progression. We discuss a girl who presented at 8 months of age with virilization, which was thought to be due to exposure to a topical testosterone preparation being used by her father. Her testosterone level did not decrease promptly after her father discontinued the medication, however, and when she followed up with signs of Cushing syndrome 5 months later, metastatic adrenocortical carcinoma was diagnosed. The patient was successfully treated with surgery and multiagent chemotherapy. Nine months after the end of treatment, her testosterone level was again found to be elevated. Testosterone precursors were now absent, however, and there were no imaging signs of recurrence. Further history showed that her father had restarted topical testosterone, and this time, exogenous exposure was correctly diagnosed. As use of topical testosterone becomes more prevalent, exogenous exposure must be considered in the differential diagnosis of childhood virilization. Any persistent testosterone elevation after exposure ceases or signs of hypercortisolism, however, are inconsistent with this diagnosis. We believe that the risk-benefit ratio favors abdominal ultrasound to rule out malignancy in all children presenting with virilization.
Copyright © 2014 by the American Academy of Pediatrics.

Entities:  

Keywords:  adrenocortical carcinoma; children; delay; diagnosis; exogenous; paternal; recurrence; testosterone; topical; virilization

Mesh:

Substances:

Year:  2014        PMID: 24799542     DOI: 10.1542/peds.2013-1454

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  1 in total

1.  Pubertal outcome in a female with virilizing adrenocortical carcinoma.

Authors:  Emily Breidbart; Tamara Cameo; James H Garvin; Hanina Hibshoosh; Sharon E Oberfield
Journal:  J Pediatr Endocrinol Metab       Date:  2016-04       Impact factor: 1.634

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.